Amir Garakani

Amir Garakani

Auto-generated profile, based on publicly available information

Amir Garakani

GARAKANI: Department of Psychiatry and Behavioral Health, Greenwich Hospital, Greenwich, CT; Department of Psychiatry, Yale University School of Medicine, New Haven, CT

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2020 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
AGAmir Garakani
Amir Garakani
JMJames W. Murrough
James W. Murrough
RFRafael C. Freire
Rafael C. Freire
RTRobyn P. Thom
Robyn P. Thom
KLKaitlyn Larkin
Kaitlyn Larkin
DIDan V. Iosifescu
Dan V. Iosifescu
Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of disability. While there continues to be expansive research in posttraumatic stress disorder (PTSD), depression and schizophrenia, there is a relative dearth of novel medications under investigation for anxiety disorders. This review's first aim is to summarize current pharmacological treatments (both approved and off-label) for panic disorder (PD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and specific phobias (SP), including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), azapirones (e.g., buspirone), mixed antidepressants (e.g., mirtazapine), antipsychotics, antihistamines (e.g., hydroxyzine), alpha- and beta-adrenergic medications (e.g., propranolol, clonidine), and GABAergic medications (benzodiazepines, pregabalin, and gabapentin). Posttraumatic stress disorder and obsessive-compulsive disorder are excluded from this review. Second, we will review novel pharmacotherapeutic agents under investigation for the treatment of anxiety disorders in adults. The pathways and neurotransmitters reviewed include serotonergic agents, glutamate modulators, GABAergic medications, neuropeptides, neurosteroids, alpha- and beta-adrenergic agents, cannabinoids, and natural remedies. The outcome of the review reveals a lack of randomized double-blind placebo- controlled trials for anxiety disorders and few studies comparing novel treatments to existing anxiolytic agents. Although there are some recent randomized controlled trials for novel agents including neuropeptides, glutamatergic agents (such as ketamine and d-cycloserine), and cannabinoids (including cannabidiol) primarily in GAD or SAD, these trials have largely been negative, with only some promise for kava and PH94B (an inhaled neurosteroid). Overall, the progression of current and future psychopharmacology research in anxiety disorders suggests that there needs to be further expansion in research of these novel pathways and larger-scale studies of promising agents with positive results from smaller trials.

1 April 2016 in The American Journal on Addictions
Verified
Journal Article
Closed access
PDF file
AGAmir Garakani
Amir Garakani
RJRobert J. Jaffe
Robert J. Jaffe
DSDipal Savla
Dipal Savla
AWAlison K. Welch
Alison K. Welch
CPCaroline A. Protin
Caroline A. Protin
DMDavid M. McDowell
David M. McDowell

1 August 2010 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
JKJohn H. Krystal
John H. Krystal
SMSanjay J. Mathew
Sanjay J. Mathew
DDD. Cyril Dʼsouza
D. Cyril Dʼsouza
AGAmir Garakani
Amir Garakani
HGHandan Gunduz-Bruce
Handan Gunduz-Bruce
DCDennis S. Charney
Dennis S. Charney

1 March 2021 in Journal of Affective Disorders
Verified
Journal Article
Closed access
MSMona Salehi
Mona Salehi
MAMan Amanat
Man Amanat
MMMohammadreza Mohammadi
Mohammadreza Mohammadi
MSMaryam Salmanian
Maryam Salmanian
NRNima Rezaei
Nima Rezaei
AGAmir Garakani
Amir Garakani

2 September 2011 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
JMJose M. Martinez
Jose M. Martinez
AGAmir Garakani
Amir Garakani
RYRachel Yehuda
Rachel Yehuda
JGJack M. Gorman
Jack M. Gorman
Background A number of studies have shown that elevated levels of inflammatory cytokines may promote depression and suicidal ideation and that neuroprotective peptides may decrease the response to stress and depression. In this study, cerebrospinal fluid (CSF) levels of three inflammatory cytokines (IL‐1, IL‐6, and tumor necrosis factor α (TNFα)) and two putative “resiliency” neuropeptides (brain‐derived neurotrophic factor (BDNF) and neuropeptide Y (NPY)) were compared between patients with depression and healthy controls. Methods Eighteen patients with major depression and 25 healthy controls underwent a lumbar puncture; CSF samples were withdrawn and assayed for IL‐1, IL‐6, TNFα, BDNF, and NPY levels. Patients with depression were then entered into an 8‐week treatment protocol and had repeated lumbar puncture procedures post‐treatment. Results Contrary to prediction, we found that at baseline depressed patients had higher CSF NPY concentration compared to the normal comparison group. Within the depressed patients, we found several statistically significant correlations between elevated CSF cytokine levels and clinical severity. Conclusion Despite the small sample size, given the challenges in obtaining CSF from patients with depression these data are of interest in confirming some aspects of the inflammatory hypothesis of depression.

1 January 2003 in American Journal of Therapeutics
Verified
Journal Article
Closed access
AGAmir Garakani
Amir Garakani
TWTerrance Win
Terrance Win
SVSubhdeep Virk
Subhdeep Virk
SGSanjay Gupta
Sanjay Gupta
DKDavid Kaplan
David Kaplan
PMPrakash S. Masand
Prakash S. Masand
Irritable bowel syndrome (IBS), a functional gastrointestinal disorder, is present in 10% to 20% of the U.S. adult population. The syndrome is best defined as chronic abdominal discomfort with changes in stool frequency, consistency, and passage, with associated symptoms such as abdominal bloating or presence of mucus in stools. Several studies have shown that up to 70% to 90% of patients with IBS who seek treatment have psychiatric comorbidity, most notably mood and anxiety disorders. Recent studies have shown a high prevalence of IBS in psychiatric patients who seek treatment, with a prevalence of 19% in schizophrenia, 29% in major depression, and 46% in panic disorder among other disorders. Our article reviews the comorbidity of IBS in psychiatric patients and discusses implications for treatment.